Search results for "percutaneous tracheostomy"

showing 3 items of 3 documents

Indication and Timing

2016

Tracheostomy is performed in patients requiring prolonged mechanical ventilation aiming at avoiding the potential detrimental effect of a sustained translaryngeal intubation (e.g. laryngeal oedema, mucosal ulcerations). Potential benefits of tracheostomy in critically ill patients are improved comfort and reduced need for sedation, easier clearance of secretions and oral hygiene, and a possible faster weaning from mechanical ventilation. Controversy exists over optimal timing (early, tracheostomy placement compared with later time points) in patients with respiratory failure. Among the published randomised controlled trials, two large studies did not report a significant advantage of an ear…

Mechanical ventilationbusiness.industrySedationmedicine.medical_treatmentIncidence (epidemiology)Settore MED/41 - AnestesiologiaPercutaneous tracheostomy in Critically ill patientsmedicine.diseaseIntensive care unitlaw.inventionPneumoniaMechanical ventilationRespiratory failurelawBlunt traumaAnesthesiamedicineIntubationmedicine.symptombusiness
researchProduct

Risk factors associated with tongue lesions:a propensity score-matched case-control study

2021

Background to analyse the potential risk factors of tongue lesions, comparing the results with a control group. Material and Methods An observational, case-control study was designed. The study included a case group comprising 336 patients with tongue lesions and 336 sex and age-matched controls. We recorded tobacco/alcohol habits, presence of dentures, allergies, medical conditions, and medications. Statistical analysis was performed via logistic regression models to estimate the odds ratio (OR) adjusted for gender, age, tobacco, and alcohol using propensity score-matching analysis (PSM). Results According to the final PSM model, patients with tongue lesions were more likely to suffer from…

Oral Medicine and PathologyResearchcoronavirusTongue Diseasessars-cov-2OtorhinolaryngologyTonguecovid-19Risk FactorsCase-Control StudiesHumanspercutaneous tracheostomySurgeryPropensity ScoreTongue FissuredGeneral DentistryUNESCO:CIENCIAS MÉDICASAged
researchProduct

Use of low dose of rFVIIa (recombinant Factor VII activated) to control late bleeding after percutaneous dilational tracheostomy

2019

Key Clinical Message In our case, the use of a low intravenous bolus dose of rFVIIa (recombinant factor VII activated; 15‐20 mcg/kg) was effective and uneventful in controlling late postprocedural PDT bleeding associated with thrombocytopenia that cannot be corrected and after all other treatments failed.

lcsh:MedicineCase ReportCase Reports030204 cardiovascular system & hematologyIntravenous boluslaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicinelawActivated factor VIIpercutaneous tracheostomyMedicinepostoperatory bleedinglcsh:R5-920activated factor VIIFactor VIIbusiness.industrylcsh:RLow doserFVIIaGeneral MedicineThrombocytopeniaPercutaneous dilational tracheostomychemistry030220 oncology & carcinogenesisAnesthesiaPercutaneous tracheostomyRecombinant DNAlcsh:Medicine (General)businessClinical Case Reports
researchProduct